Aclaris Therapeutics (NASDAQ:ACRS) specializes in developing novel drug candidates and therapies in dermatology and immunology. The company focuses on addressing unmet needs for patients with conditions stemming from immuno-inflammatory responses. Aclaris is actively involved in a range of projects, emphasizing innovation in the treatment of skin diseases and hair loss, among other health concerns. Their objectives include advancing their pipeline products through clinical trials with the goal of achieving market approval and creating effective treatments that improve patients' quality of life. Through rigorous research and development efforts, Aclaris aims to bring transformative therapies to the market, targeting conditions with significant patient impact.